共 462 条
[1]
O’Shea JJ(2015)The JAK-STAT pathway: impact on human disease and therapeutic intervention Annu Rev Med 66 311-28
[2]
Schwartz DM(2008)Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment Leukemia 22 437-438
[3]
Villarino AV(2018)Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia Leuk Res 69 100-102
[4]
Gadina M(2004)Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia Am J Med 117 755-761
[5]
MCInnes IB(2007)International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT) Leuk Res 31 737-40
[6]
Laurence A(2020)Epidemiology of the classical myeloproliferative neoplasms: the four corners of an expansive and complex map Blood Rev 42 100706-702
[7]
Barosi G(2022)Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States Leuk Lymphoma 63 694-2513
[8]
Mesa RA(2014)Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis Blood 124 2507-3184
[9]
Thiele J(2011)Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study J Clin Oncol 29 3179-1881
[10]
Cervantes F(2013)Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study Leukemia 27 1874-1708